NiKang Therapeutics is a clinical-stage biotech focused on discovering and developing innovative small-molecule oncology medicines. The company’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design to rapidly identify candidates with desirable pharmacological features. Its pipeline includes a differentiated HIF-2 alpha inhibitor and other lead candidates intended to be advanced into the clinic. Proceeds from the financing will be used to advance lead drug candidates into the clinic, expand the pipeline, and fund internal drug discovery programs. CBC Group incubated the company and NiKang emphasizes deep insights into disease biology and molecular pathways for target selection. The company has added board members in connection with the financing and is positioning to grow into a leading precision oncology company. NiKang Therapeutics was founded and incubated by CBC Group in late 2017 and is focused on discovering and developing innovative small-molecule medicines to address unmet medical needs. The company has made progress identifying development candidates for several difficult-to-drug targets. NiKang's pipeline centers on oncology programs, and the company plans to advance multiple candidates through preclinical and clinical development. CBC provides strategic direction, operational assistance, and financial support to NiKang. The company completed a significant financing in 2020 that strengthened its balance sheet to support its R&D plans. No operating metrics (revenue/users) are provided in the articles.

Total raised

$250M

Funding rounds

2

Latest round

Series C

Latest activity

May 2021